Grazoprevir and Elbasvir in Patients with Genotype 1 Hepatitis C Virus Infection: A Comprehensive Efficacy and Safety Analysis
Table 3
Subgroup analysis of SVR12.
Variables
Total, n/N
SVR12 (95% CI), %
Treatment-naive (n/N, %)
Previously treated (n/N, %)
Sex
Male
260/280
93 (89–96)
217/234 (93)
43/46 (93)
1.000
Female
237/244
97 (94–99)
204/211 (97)
33/33 (100)
0.598
Age
≥65 years
39/40
98 (87–100)
29/29 (100)
10/11 (91)
0.275
65 years
336/355
95 (92–97)
270/287 (95)
66/68 (97)
0.548
Race
White
365/385
95 (92–97)
291/308 (94)
74/77 (96)
0.776
Nonwhite
132/139
95 (90–98)
130/137 (95)
2/2 (100)
1.000
Genotype
1a
250/269
93 (89–96)
222/239 (93)
28/30 (93)
1.000
1b
219/225
97 (94–99)
171/176 (97)
48/49 (98)
1.000
1-other
28/30
93 (78–99)
28/30 (93)
0
—
IL 28B genotype
CC
127/136
93 (88–97)
125/134 (93)
2/2 (100)
1.000
Non-CC
368/385
96 (93–97)
294/308 (95)
74/77 (96)
1.000
Unknown
1/1
100 (25–100)
1/1 (100)
0
—
Baseline HCV RNA
≤800000 IU/mL
153/156
98 (94–100)
126/127 (99)
27/29 (93)
0.089
>800000 IU/mL
344/368
93 (90–96)
295/318 (93)
49/50 (98)
0.225
NS3/4A RAS at baseline
Baseline RAS
138/145
95 (90–98)
107/111 (96)
31/34 (91)
0.355
No baseline RAS
206/213
97 (93–99)
162/169 (96)
44/44 (100)
0.349
NS5A RAS at baseline
Baseline RAS
34/45
76 (60–87)
28/37 (76)
6/8 (75)
1.000
No baseline RAS
315/318
99 (97–100)
245/247 (99)
70/71 (99)
0.533
Three articles reporting the variables were included [13–15]. One of the three articles not reporting the variable was excluded [13]. Three articles were included. Two patients were missing data for IL28B genotype and were excluded. SVR12 was achieved in 1 of these 2 patients (50.0%, CI: 1.3% to 98.7%). One of the three articles not reporting the variable was excluded [2], and only genotypes 1a and 1b were reported. One of 79 patients in study 4 was sequenced of NS5A but not sequenced of NS3/4A. They were compared between treatment-naïve and previously treated groups.
